{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:15:29Z","timestamp":1792494929094,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006919","name":"Massachusetts Institute of Technology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006919","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Understanding health-related quality of life (HRQoL) dynamics is essential for assessing and improving treatment experiences; however, clinical and observational studies struggle to capture their full complexity. We use simulation modeling and the case of Chimeric Antigen Receptor T-cell therapy\u2014a type of cancer immunotherapy that can prolong survival, but carries life-threatening risks\u2014to study HRQoL dynamics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We developed an exploratory system dynamics model with mathematical equations and parameter values informed by literature and expert insights.\u00a0We refined its feedback structure and evaluated its dynamic behavior through iterative interviews. Model simulated HRQoL from treatment approval through six months post-infusion. Two strategies\u2014reducing the delay to infusion and enhancing social support\u2014were incorporated into the model. To dynamically evaluate the effect of these strategies, we developed four metrics: post-treatment HRQoL decline, recovery time to pre-treatment HRQoL, post-treatment HRQoL peak, and durability of the peak.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Model captures key interactions within HRQoL, providing a nuanced analysis of its continuous temporal dynamics, particularly physical well-being, psychological well-being, tumor burden, receipt and efficacy of treatment, side effects, and their management. Model analysis shows reducing infusion delays enhanced HRQoL across all four metrics. While enhanced social support improved the first three metrics for patients who received treatment, it did not change durability of the peak.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Simulation modeling can help explore the effects of strategies on HRQoL while also demonstrating the dynamic interactions between its key components, offering a powerful tool to investigate aspects of HRQoL that are difficult to assess in real-world settings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11136-024-03810-0","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:17:46Z","timestamp":1730305066000},"page":"273-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health-related quality of life dynamics: modeling insights from immunotherapy"],"prefix":"10.1007","volume":"34","author":[{"given":"Zeynep","family":"Hasgul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Spanjaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumreen","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Akhavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"3810_CR1","doi-asserted-by":"publisher","unstructured":"Beaulieu E, Spanjaart A, Roes A, Rachet B, Dalle S, Kersten MJ, Maucort-Boulch D, Jalali MS. Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams. Quality of Life Research, 31, 2357\u201366. https:\/\/doi.org\/10.1007\/s11136-022-03110-5","DOI":"10.1007\/s11136-022-03110-5"},{"key":"3810_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","volume":"118","author":"GH Guyatt","year":"1993","unstructured":"Guyatt, G. H., Feeny, D. H., & Patrick, D. L. (1993). Measuring health-related quality of life. Annals of Internal Medicine, 118, 622\u2013629. https:\/\/doi.org\/10.7326\/0003-4819-118-8-199304150-00009","journal-title":"Annals of Internal Medicine"},{"key":"3810_CR3","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/EPIREV\/MXAB006","volume":"43","author":"MS Jalali","year":"2021","unstructured":"Jalali, M. S., Digennaro, C., Guitar, A., et al. (2021). Evolution and reproducibility of Simulation modeling in Epidemiology and Health Policy over half a century. Epidemiologic Reviews, 43, 166\u2013175. https:\/\/doi.org\/10.1093\/EPIREV\/MXAB006","journal-title":"Epidemiologic Reviews"},{"key":"3810_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/J.JVAL.2014.12.001","volume":"18","author":"DA Marshall","year":"2015","unstructured":"Marshall, D. A., Burgos-Liz, L., Ijzerman, M. J., et al. (2015). Applying dynamic simulation modeling methods in health care delivery research-the SIMULATE checklist: Report of the ISPOR simulation modeling emerging good practices task force. Value In Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 18, 5\u201316. https:\/\/doi.org\/10.1016\/J.JVAL.2014.12.001","journal-title":"Value In Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"key":"3810_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/NRD.2017.196","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard, A. (2017). FDA approves first CAR T therapy. Nature Reviews. Drug Discovery, 16, 669. https:\/\/doi.org\/10.1038\/NRD.2017.196","journal-title":"Nature Reviews. Drug Discovery"},{"key":"3810_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/D41573-021-00031-9","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. (2021). FDA approves fourth CAR-T cell therapy. Nature Reviews. Drug Discovery, 20, 166. https:\/\/doi.org\/10.1038\/D41573-021-00031-9","journal-title":"Nature Reviews. Drug Discovery"},{"key":"3810_CR7","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1001\/JAMA.2020.15456","volume":"324","author":"R Voelker","year":"2020","unstructured":"Voelker, R. (2020). CAR-T therapy is approved for Mantle Cell Lymphoma. Journal of the American Medical Association, 324, 832\u2013832. https:\/\/doi.org\/10.1001\/JAMA.2020.15456","journal-title":"Journal of the American Medical Association"},{"key":"3810_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/2159-8290.CD-NB2017-155","volume":"8","author":"FDA Approves Second CAR T-cell Therapy","year":"2018","unstructured":"FDA Approves Second CAR T-cell Therapy (2018). Cancer Discovery. ;8:5\u20136. doi: https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2017-155\/335933\/P\/FDA-APPROVES-SECOND-CAR-T-CELL-THERAPYFDA-APPROVES.","journal-title":"Cancer Discovery"},{"key":"3810_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/D41573-021-00063-1","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. (2021). FDA approves first BCMA-targeted CAR-T cell therapy. Nature Reviews. Drug Discovery, 20, 332. https:\/\/doi.org\/10.1038\/D41573-021-00063-1","journal-title":"Nature Reviews. Drug Discovery"},{"key":"3810_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMOA1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster, S. J., Bishop, M. R., Tam, C. S., et al. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. New England Journal of Medicine, 380, 45\u201356. https:\/\/doi.org\/10.1056\/NEJMOA1804980","journal-title":"New England Journal of Medicine"},{"key":"3810_CR11","doi-asserted-by":"publisher","unstructured":"Porter, D. L., Hwang, W. T., Frey, N. V., et al. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 7. https:\/\/doi.org\/10.1126\/SCITRANSLMED.AAC5415","DOI":"10.1126\/SCITRANSLMED.AAC5415"},{"key":"3810_CR12","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah, N. N., Lee, D. W., Yates, B., et al. (2021). Long-term Follow-Up of CD19-CAR T-Cell therapy in children and young adults with B-ALL. Journal of Clinical Oncology, 39, 1650\u20131659. https:\/\/doi.org\/10.1200\/JCO.20.02262","journal-title":"Journal of Clinical Oncology"},{"key":"3810_CR13","doi-asserted-by":"publisher","unstructured":"Elsallab, M., Ellithi, M., Hempel, S., et al. (2023). Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis. Cancer Gene Therapy 2023, 1\u201310. https:\/\/doi.org\/10.1038\/s41417-023-00593-3","DOI":"10.1038\/s41417-023-00593-3"},{"key":"3810_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L., Ghobadi, A., Jacobson, C. A., et al. (2019). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial. The Lancet Oncology, 20, 31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"The Lancet Oncology"},{"key":"3810_CR15","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/BLOOD-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N., & Kochenderfer, J. N. (2016). Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood, 127, 3321\u20133330. https:\/\/doi.org\/10.1182\/BLOOD-2016-04-703751","journal-title":"Blood"},{"key":"3810_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/J.BBMT.2019.09.037","volume":"26","author":"J Ruark","year":"2020","unstructured":"Ruark, J., Mullane, E., Cleary, N., et al. (2020). Patient-reported neuropsychiatric outcomes of long-term survivors after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 26, 34\u201343. https:\/\/doi.org\/10.1016\/J.BBMT.2019.09.037","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"3810_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/J.JTCT.2022.09.029","volume":"29","author":"MR Taylor","year":"2023","unstructured":"Taylor, M. R., Steineck, A., Lahijani, S., et al. (2023). Biobehavioral Implications of Chimeric Antigen Receptor T-cell therapy: Current state and future directions. Transplant Cell Ther, 29, 19\u201326. https:\/\/doi.org\/10.1016\/J.JTCT.2022.09.029","journal-title":"Transplant Cell Ther"},{"key":"3810_CR18","doi-asserted-by":"publisher","first-page":"e786","DOI":"10.1016\/S2352-3026(22)00226-5","volume":"9","author":"N Gagelmann","year":"2022","unstructured":"Gagelmann, N., Sureda, A., Montoto, S., et al. (2022). Access to and affordability of CAR T-cell therapy in multiple myeloma: An EBMT position paper. Lancet Haematol, 9, e786\u2013e795. https:\/\/doi.org\/10.1016\/S2352-3026(22)00226-5","journal-title":"Lancet Haematol"},{"key":"3810_CR19","doi-asserted-by":"publisher","first-page":"e802","DOI":"10.1097\/HS9.0000000000000802","volume":"6","author":"F Efficace","year":"2022","unstructured":"Efficace, F., Cannella, L., Sparano, F., et al. (2022). Chimeric Antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: A scoping review. Hemasphere, 6, e802. https:\/\/doi.org\/10.1097\/HS9.0000000000000802","journal-title":"Hemasphere"},{"key":"3810_CR20","doi-asserted-by":"publisher","first-page":"S147","DOI":"10.1002\/JCPH.1691","volume":"60","author":"A Chaudhury","year":"2020","unstructured":"Chaudhury, A., Zhu, X., Chu, L., et al. (2020). Chimeric Antigen Receptor T Cell Therapies: A review of Cellular Kinetic-Pharmacodynamic modeling approaches. The Journal of Clinical Pharmacology, 60, S147\u2013S159. https:\/\/doi.org\/10.1002\/JCPH.1691","journal-title":"The Journal of Clinical Pharmacology"},{"key":"3810_CR21","doi-asserted-by":"publisher","unstructured":"Vinke, P. C., Combalia, M., De Bock, G. H., et al. (2023). Monitoring multidimensional aspects of quality of life after cancer immunotherapy: Protocol for the international multicentre, observational QUALITOP cohort study. British Medical Journal Open, 13. https:\/\/doi.org\/10.1136\/BMJOPEN-2022-069090","DOI":"10.1136\/BMJOPEN-2022-069090"},{"key":"3810_CR22","unstructured":"Sterman, J. (2000). Business Dynamics: Systems Thinking and Modeling for a Complex World. Irwin McGraw-Hill, Boston."},{"key":"3810_CR23","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1136\/jitc-2022-005360","volume":"10","author":"L Liu","year":"2022","unstructured":"Liu, L., Ma, C., Zhang, Z., et al. (2022). Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. Journal for Immunotherapy of Cancer, 10, 5360. https:\/\/doi.org\/10.1136\/jitc-2022-005360","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"3810_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/CTS.12636","volume":"12","author":"D Hardiansyah","year":"2019","unstructured":"Hardiansyah, D., & Ng, C. M. (2019). Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell therapy. Clinical and Translational Science, 12, 343\u2013349. https:\/\/doi.org\/10.1111\/CTS.12636","journal-title":"Clinical and Translational Science"},{"key":"3810_CR25","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/CPT.2040","volume":"109","author":"C Liu","year":"2021","unstructured":"Liu, C., Ayyar, V. S., Zheng, X., et al. (2021). Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T cells in humans. Clinical Pharmacology and Therapeutics, 109, 716\u2013727. https:\/\/doi.org\/10.1002\/CPT.2040","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"3810_CR26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1037\/A0031603","volume":"18","author":"PR Deboeck","year":"2013","unstructured":"Deboeck, P. R., & Bergeman, C. S. (2013). The Reservoir Model: A Differential equation model of psychological regulation. Psychological Methods, 18, 237. https:\/\/doi.org\/10.1037\/A0031603","journal-title":"Psychological Methods"},{"key":"3810_CR27","doi-asserted-by":"publisher","unstructured":"Carrero, G., Makin, J., Malinowski, P. (2002). A mathematical model for the dynamics of happiness. Mathematical Biosciences and Engineering 2022 2: 2022;19:2002\u201329. https:\/\/doi.org\/10.3934\/MBE.2022094","DOI":"10.3934\/MBE.2022094"},{"key":"3810_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/SPC3.12074","volume":"7","author":"C Wrosch","year":"2013","unstructured":"Wrosch, C., Scheier, M. F., & Miller, G. E. (2013). Goal Adjustment Capacities, Subjective Well-Being, and Physical Health. Soc Personal Psychol Compass, 7, 847. https:\/\/doi.org\/10.1111\/SPC3.12074","journal-title":"Soc Personal Psychol Compass"},{"key":"3810_CR29","doi-asserted-by":"publisher","unstructured":"Barlas, Y. (1996). Formal aspects of model validity and validation in system dynamics. System Dynamics Review: The Journal of the System Dynamics Society, 12, 183-210. https:\/\/doi.org\/10.1002\/(SICI)1099-1727(199623)12:3%3C183::AID-SDR103%3E3.0.CO;2-4","DOI":"10.1002\/(SICI)1099-1727(199623)12:3%3C183::AID-SDR103%3E3.0.CO;2-4"},{"key":"3810_CR30","doi-asserted-by":"publisher","unstructured":"Spanjaart, A. M., Pennings, E. R. A., Mutsaers, P. G. N. J., et al. (2023). The Dutch CAR-T tumorboard experience: Population-based real-World Data on patients with relapsed or refractory large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell therapy in the Netherlands. Cancers (Basel), 15. https:\/\/doi.org\/10.3390\/CANCERS15174334","DOI":"10.3390\/CANCERS15174334"},{"key":"3810_CR31","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/BLOODADVANCES.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino, L., Di Blasi, R., Kanoun, S., et al. (2020). Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv, 4, 5607\u20135615. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020003001","journal-title":"Blood Adv"},{"key":"3810_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/BLOOD.2021015209","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge, W. A., Martus, P., Schmitt, M., et al. (2022). GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood, 140, 349\u2013358. https:\/\/doi.org\/10.1182\/BLOOD.2021015209","journal-title":"Blood"},{"key":"3810_CR33","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1182\/BLOOD-2021-147670","volume":"138","author":"M Bastos-Oreiro","year":"2021","unstructured":"Bastos-Oreiro, M., Gutierrez, A., Reguera, J. L., et al. (2021). Rreal-world results from Anti-CD19 CAR-T cell therapy for relapsed or refractory diffuse large B-Cell lymphoma in Spain and comparison with previous Standard of Care: A Geltamo\/Geth study. Blood, 138, 3850. https:\/\/doi.org\/10.1182\/BLOOD-2021-147670","journal-title":"Blood"},{"key":"3810_CR34","doi-asserted-by":"publisher","unstructured":"Alm\u00e5sbak, H., Aarvak, T., & Vemuri, M. C. (2016). CAR T cell therapy: A game changer in Cancer Treatment. J Immunol Res, 2016. https:\/\/doi.org\/10.1155\/2016\/5474602","DOI":"10.1155\/2016\/5474602"},{"key":"3810_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3747\/CO.27.5283","volume":"27","author":"DA Wall","year":"2020","unstructured":"Wall, D. A., & Krueger, J. (2020). Chimeric antigen receptor T cell therapy comes to clinical practice. Current Oncology (Toronto, Ont.), 27, 115\u2013123. https:\/\/doi.org\/10.3747\/CO.27.5283","journal-title":"Current Oncology (Toronto, Ont.)"},{"key":"3810_CR36","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/J.JVAL.2022.02.007","volume":"25","author":"AJ Chen","year":"2022","unstructured":"Chen, A. J., Zhang, J., Agarwal, A., et al. (2022). Value of Reducing Wait Times for Chimeric Antigen Receptor T-Cell treatment: Evidence from Randomized Controlled Trial Data on Tisagenlecleucel for diffuse large B-Cell lymphoma. Value in Health, 25, 1344\u20131351. https:\/\/doi.org\/10.1016\/J.JVAL.2022.02.007","journal-title":"Value in Health"},{"key":"3810_CR37","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.21873\/ANTICANRES.12536","volume":"38","author":"Z Al-Qurayshi","year":"2018","unstructured":"Al-Qurayshi, Z., Crowther, J. E., Hamner, J. B., et al. (2018). Disparities of Immunotherapy utilization in patients with stage III cutaneous melanoma: A National Perspective. Anticancer Research, 38, 2897\u20132901. https:\/\/doi.org\/10.21873\/ANTICANRES.12536","journal-title":"Anticancer Research"},{"key":"3810_CR38","doi-asserted-by":"publisher","unstructured":"Milton, S., Emery, J. D., Rinaldi, J., et al. (2022). Exploring a novel method for optimising the implementation of a colorectal cancer risk prediction tool into primary care: A qualitative study. Implement Sci, 17. https:\/\/doi.org\/10.1186\/S13012-022-01205-8","DOI":"10.1186\/S13012-022-01205-8"},{"key":"3810_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4274\/TJH.GALENOS.2022.2022.0193","volume":"39","author":"E Erdogan","year":"2022","unstructured":"Erdogan, E., Yalcin, K., Hemsinlioglu, C., et al. (2022). Preliminary Report of the academic CAR-T (ISIKOK-19) cell clinical trial in Turkey: Characterization of product and outcomes of clinical application. Turk J Haematol, 39, 206\u2013210. https:\/\/doi.org\/10.4274\/TJH.GALENOS.2022.2022.0193","journal-title":"Turk J Haematol"},{"key":"3810_CR40","doi-asserted-by":"publisher","first-page":"573179","DOI":"10.3389\/FIMMU.2020.573179\/BIBTEX","volume":"11","author":"I Ortiz de Landazuri","year":"2020","unstructured":"Ortiz de Landazuri, I., Egri, N., Mu\u00f1oz-S\u00e1nchez, G., et al. (2020). Manufacturing and Management of CAR T-Cell Therapy in COVID-19\u2019s time: Central Versus Point of Care proposals. Frontiers in Immunology, 11, 573179. https:\/\/doi.org\/10.3389\/FIMMU.2020.573179\/BIBTEX","journal-title":"Frontiers in Immunology"},{"key":"3810_CR41","unstructured":"Support at home for You and your family | Cancer in general | Cancer Research UK. https:\/\/www.cancerresearchuk.org\/about-cancer\/coping\/practically\/support-at-home (accessed 28 June 2024)."},{"key":"3810_CR42","unstructured":"Road To Recovery | American Cancer Society https:\/\/www.cancer.org\/support-programs-and-services\/road-to-recovery.html (accessed 28 June 2024)."},{"key":"3810_CR43","unstructured":"Care Calendar Website | Lotsa Helping Hands (June 2024). https:\/\/lotsahelpinghands.com\/ (accessed 28."},{"key":"3810_CR44","unstructured":"Comfort, & Cuisine by MOQC & HBOM \u2013 Meal delivery for patients undergoing cancer treatment. https:\/\/comfortcuisine.moqc.org\/ (accessed 28 June 2024)."},{"key":"3810_CR45","unstructured":"Macmillan Cancer Support | The UK\u2019s leading cancer care charity. https:\/\/www.macmillan.org.uk\/ (accessed 28 June 2024)."},{"key":"3810_CR46","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1001\/JAMAONCOL.2019.0011","volume":"5","author":"AL Cheville","year":"2019","unstructured":"Cheville, A. L., Moynihan, T., Herrin, J., et al. (2019). Effect of Collaborative Telerehabilitation on Functional Impairment and Pain among patients with Advanced-Stage Cancer: A Randomized Clinical Trial. JAMA Oncol, 5, 644\u2013652. https:\/\/doi.org\/10.1001\/JAMAONCOL.2019.0011","journal-title":"JAMA Oncol"},{"key":"3810_CR47","doi-asserted-by":"publisher","unstructured":"Frick, J., Gebert, P., Grittner, U., et al. (2022). Identifying and handling unbalanced baseline characteristics in a non-randomized, controlled, multicenter social care nurse intervention study for patients in advanced stages of cancer. Bmc Cancer, 22. https:\/\/doi.org\/10.1186\/S12885-022-09646-6","DOI":"10.1186\/S12885-022-09646-6"},{"key":"3810_CR48","doi-asserted-by":"publisher","unstructured":"Steineck, A., Wiener, L., Mack, J. W., et al. (2020). Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy. Pediatric Blood & Cancer, 67. https:\/\/doi.org\/10.1002\/PBC.28249","DOI":"10.1002\/PBC.28249"},{"key":"3810_CR49","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/J.BBI.2007.03.005","volume":"21","author":"BL Andersen","year":"2007","unstructured":"Andersen, B. L., Farrar, W. B., Golden-Kreutz, D., et al. (2007). Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain, Behavior, and Immunity, 21, 953\u2013961. https:\/\/doi.org\/10.1016\/J.BBI.2007.03.005","journal-title":"Brain, Behavior, and Immunity"},{"key":"3810_CR50","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1002\/CNCR.23969","volume":"113","author":"BL Andersen","year":"2008","unstructured":"Andersen, B. L., Yang, H. C., Farrar, W. B., et al. (2008). Psychologic intervention improves survival for breast cancer patients: A randomized clinical trial. Cancer, 113, 3450\u20133458. https:\/\/doi.org\/10.1002\/CNCR.23969","journal-title":"Cancer"},{"key":"3810_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.19.00086","volume":"3","author":"S Tully","year":"2019","unstructured":"Tully, S., Feng, Z., Grindrod, K., et al. (2019). Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell therapy in large B-Cell lymphoma: A Discrete Event Simulation Model. JCO Clin Cancer Inform, 3, 1\u20139. https:\/\/doi.org\/10.1200\/CCI.19.00086","journal-title":"JCO Clin Cancer Inform"},{"key":"3810_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTCT.2022.12.021","author":"H Hubbeling","year":"2022","unstructured":"Hubbeling, H., Silverman, E. A., Michaud, L., et al. (2022). Bridging Radiation rapidly and effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas prior to Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther Published Online First: December. https:\/\/doi.org\/10.1016\/J.JTCT.2022.12.021","journal-title":"Transplant Cell Ther Published Online First: December"},{"key":"3810_CR53","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/AJH.26583","volume":"97","author":"J Du","year":"2022","unstructured":"Du, J., Wei, R., Jiang, S., et al. (2022). CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed\/refractory multiple myeloma, including cases with poor performance status. American Journal of Hematology, 97, 933\u2013941. https:\/\/doi.org\/10.1002\/AJH.26583","journal-title":"American Journal of Hematology"},{"key":"3810_CR54","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jtct.2022.01.024","volume":"28","author":"R Puckrin","year":"2022","unstructured":"Puckrin, R., Stewart, D. A., & Shafey, M. (2022). Real-world eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in large B cell lymphoma: A Population-based analysis. Transplant Cell Ther, 28, 218. .e1-218.e4","journal-title":"Transplant Cell Ther"},{"key":"3810_CR55","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/S00520-021-06425-0","volume":"30","author":"T Gordon","year":"2022","unstructured":"Gordon, T., Lee, L. J., Tchangalova, N., et al. (2022). Psychosocial protective interventions associated with a better quality of life and psychological wellbeing for African American\/Black female breast cancer survivors: An integrative review. Supportive Care in Cancer, 30, 1093\u20131114. https:\/\/doi.org\/10.1007\/S00520-021-06425-0","journal-title":"Supportive Care in Cancer"},{"key":"3810_CR56","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/JAMA.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler, R. C., Berglund, P., Demler, O., et al. (2003). The epidemiology of major depressive disorder: Results from the National Comorbidity Survey replication (NCS-R). Journal of the American Medical Association, 289, 3095\u20133105. https:\/\/doi.org\/10.1001\/JAMA.289.23.3095","journal-title":"Journal of the American Medical Association"},{"key":"3810_CR57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/S10943-017-0447-4","volume":"57","author":"C Malone","year":"2018","unstructured":"Malone, C., & Wachholtz, A. (2018). The relationship of anxiety and depression to Subjective Well-being in a mainland Chinese sample. Journal of Religion and Health, 57, 266. https:\/\/doi.org\/10.1007\/S10943-017-0447-4","journal-title":"Journal of Religion and Health"},{"key":"3810_CR58","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/J.GENHOSPPSYCH.2009.04.002","volume":"31","author":"B Roshanaei-Moghaddam","year":"2009","unstructured":"Roshanaei-Moghaddam, B., Katon, W. J., & Russo, J. (2009). The longitudinal effects of depression on physical activity. General Hospital Psychiatry, 31, 306\u2013315. https:\/\/doi.org\/10.1016\/J.GENHOSPPSYCH.2009.04.002","journal-title":"General Hospital Psychiatry"},{"key":"3810_CR59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/J.JPSYCHIRES.2021.02.019","volume":"136","author":"D Za\u00e7e","year":"2021","unstructured":"Za\u00e7e, D., Hoxhaj, I., Orfino, A., et al. (2021). Interventions to address mental health issues in healthcare workers during infectious disease outbreaks: A systematic review. Journal of Psychiatric Research, 136, 319\u2013333. https:\/\/doi.org\/10.1016\/J.JPSYCHIRES.2021.02.019","journal-title":"Journal of Psychiatric Research"},{"key":"3810_CR60","first-page":"22","volume":"60","author":"K P\u00e9ter","year":"2016","unstructured":"P\u00e9ter, K., Gitta, P., Krisztina, M., et al. (2016). Psychological aspects of immunotherapies in the treatment of malignant melanoma. Magyar Onkologia, 60, 22\u201327.","journal-title":"Magyar Onkologia"},{"key":"3810_CR61","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/J.GERINURSE.2015.02.022","volume":"36","author":"KD Wright","year":"2015","unstructured":"Wright, K. D., Pepper, G. A., Caserta, M., et al. (2015). Factors that influence physical function and emotional well-being among Medicare-Medicaid enrollees. Geriatric Nursing (New York, N.Y.), 36, S16. https:\/\/doi.org\/10.1016\/J.GERINURSE.2015.02.022","journal-title":"Geriatric Nursing (New York, N.Y.)"},{"key":"3810_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/S11764-007-0014-1","volume":"1","author":"CM Alfano","year":"2007","unstructured":"Alfano, C. M., Smith, A. W., Irwin, M. L., et al. (2007). Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: A prospective analysis. Journal of Cancer Survivorship, 1, 116. https:\/\/doi.org\/10.1007\/S11764-007-0014-1","journal-title":"Journal of Cancer Survivorship"},{"key":"3810_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1359105307084318","volume":"13","author":"LR Vartanian","year":"2008","unstructured":"Vartanian, L. R., & Shaprow, J. G. (2008). Effects of weight stigma on exercise motivation and behavior: A preliminary investigation among college-aged females. Journal of Health Psychology, 13, 131\u2013138. https:\/\/doi.org\/10.1177\/1359105307084318","journal-title":"Journal of Health Psychology"},{"key":"3810_CR64","doi-asserted-by":"publisher","unstructured":"Rice, J., Nagel, S., Randall, J., et al. (2019). Chimeric Antigen Receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and Approach to Treatment. Curr Treat Options Neurol, 21. https:\/\/doi.org\/10.1007\/S11940-019-0580-3","DOI":"10.1007\/S11940-019-0580-3"},{"key":"3810_CR65","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso, B. D., Nastoupil, L. J., Adkins, S., et al. (2021). Management of Immune-related adverse events in patients treated with chimeric Antigen receptor T-Cell therapy: ASCO Guideline. Journal of Clinical Oncology, 39, 3978\u20133992. https:\/\/doi.org\/10.1200\/JCO.21.01992","journal-title":"Journal of Clinical Oncology"},{"key":"3810_CR66","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/J.GENHOSPPSYCH.2017.06.005","volume":"49","author":"EA Awick","year":"2017","unstructured":"Awick, E. A., Ehlers, D. K., Agui\u00f1aga, S., et al. (2017). Effects of a randomized exercise trial on physical activity, psychological distress and quality of life in older adults. General Hospital Psychiatry, 49, 44\u201350. https:\/\/doi.org\/10.1016\/J.GENHOSPPSYCH.2017.06.005","journal-title":"General Hospital Psychiatry"},{"key":"3810_CR67","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/TBM\/IBZ198","volume":"10","author":"DX Marquez","year":"2020","unstructured":"Marquez, D. X., Aguin\u00e3ga, S., V\u00e1squez, P. M., et al. (2020). A systematic review of physical activity and quality of life and well-being. Transl Behav Med, 10, 1098. https:\/\/doi.org\/10.1093\/TBM\/IBZ198","journal-title":"Transl Behav Med"},{"key":"3810_CR68","first-page":"650","volume":"81","author":"MR Baldwin","year":"2015","unstructured":"Baldwin, M. R. (2015). Measuring and Predicting Long-Term outcomes in older survivors of critical illness. Minerva Anestesiologica, 81, 650.","journal-title":"Minerva Anestesiologica"},{"key":"3810_CR69","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/S10865-012-9453-X","volume":"36","author":"JR Schumacher","year":"2013","unstructured":"Schumacher, J. R., Palta, M., Loconte, N. K., et al. (2013). Characterizing the psychological distress response before and after a cancer diagnosis. Journal of Behavioral Medicine, 36, 591\u2013600. https:\/\/doi.org\/10.1007\/S10865-012-9453-X","journal-title":"Journal of Behavioral Medicine"},{"key":"3810_CR70","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah, B. D., Ghobadi, A., Oluwole, O. O., et al. (2021). KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, 398, 491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8","journal-title":"Lancet"},{"key":"3810_CR71","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.6004\/JNCCN.2007.0088","volume":"5","author":"V Mock","year":"2007","unstructured":"Mock, V., Abernethy, A. P., Atkinson, A., et al. (2007). Cancer-related fatigue clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 5, 1054\u20131078. https:\/\/doi.org\/10.6004\/JNCCN.2007.0088","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"key":"3810_CR72","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/J.BBMT.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey, N., & Porter, D. (2019). Cytokine release syndrome with Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 25, e123\u2013e127. https:\/\/doi.org\/10.1016\/J.BBMT.2018.12.756","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"3810_CR73","doi-asserted-by":"publisher","unstructured":"Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J, 11. https:\/\/doi.org\/10.1038\/S41408-021-00459-7","DOI":"10.1038\/S41408-021-00459-7"},{"key":"3810_CR74","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1016\/J.JPAINSYMMAN.2021.02.034","volume":"62","author":"KA Bland","year":"2021","unstructured":"Bland, K. A., Harrison, M., Zopf, E. M., et al. (2021). Quality of life and Symptom Burden improve in patients attending a Multidisciplinary Clinical Service for Cancer Cachexia: A retrospective Observational Review. J Pain Symptom Manage, 62, e164\u2013e176. https:\/\/doi.org\/10.1016\/J.JPAINSYMMAN.2021.02.034","journal-title":"J Pain Symptom Manage"},{"key":"3810_CR75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/J.1365-2354.2008.01021.X","volume":"18","author":"A Siddiqi","year":"2009","unstructured":"Siddiqi, A., Given, C. W., Given, B., et al. (2009). Quality of life among patients with primary, metastatic and recurrent cancer. Eur J Cancer Care (Engl), 18, 84\u201396. https:\/\/doi.org\/10.1111\/J.1365-2354.2008.01021.X","journal-title":"Eur J Cancer Care (Engl)"},{"key":"3810_CR76","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jtct.2022.12.021","volume":"29","author":"H Hubbeling","year":"2023","unstructured":"Hubbeling, H., Silverman, E. A., Michaud, L., et al. (2023). Bridging Radiation rapidly and effectively Cytoreduces High-Risk Relapsed\/Refractory Aggressive B Cell Lymphomas prior to Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther, 29, 259. .e1-259.e10","journal-title":"Transplant Cell Ther"},{"key":"3810_CR77","doi-asserted-by":"publisher","unstructured":"Rotte, A., Frigault, M. J., Ansari, A., et al. (2022). Dose-response correlation for CAR-T cells: A systematic review of clinical studies. Journal for Immunotherapy of Cancer, 10. https:\/\/doi.org\/10.1136\/JITC-2022-005678","DOI":"10.1136\/JITC-2022-005678"},{"issue":"Suppl 1","key":"3810_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/HON.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer, D., & Brentjens, R. (2019). CAR T-cell therapy: Full speed ahead. Hematological Oncology, 37(Suppl 1), 95\u2013100. https:\/\/doi.org\/10.1002\/HON.2591","journal-title":"Hematological Oncology"},{"key":"3810_CR79","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/BJH.18209","volume":"198","author":"A Kuhnl","year":"2022","unstructured":"Kuhnl, A., Roddie, C., Kirkwood, A. A., et al. (2022). A national service for delivering CD19 CAR-Tin large B-cell lymphoma - the UK real-world experience. British Journal of Haematology, 198, 492\u2013502. https:\/\/doi.org\/10.1111\/BJH.18209","journal-title":"British Journal of Haematology"},{"key":"3810_CR80","doi-asserted-by":"publisher","unstructured":"Wu, C., Te, Huang, Y. C., Chen, W. C., et al. (2019). Effect of Tumor Burden on Tumor Aggressiveness and Immune Modulation in prostate Cancer: Association with IL-6 signaling. Cancers (Basel), 11. https:\/\/doi.org\/10.3390\/CANCERS11070992","DOI":"10.3390\/CANCERS11070992"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03810-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-024-03810-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-024-03810-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T14:14:02Z","timestamp":1738851242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-024-03810-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3810"],"URL":"https:\/\/doi.org\/10.1007\/s11136-024-03810-0","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"9 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants or animals. All data used in this study were obtained from publicly available sources or previously published literature, and no new data were collected for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study did not involve human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}},{"value":"The authors have no relevant financial or non-financial interests to disclose. MJK reported receiving honoraria from and has a consulting\/advisory role for BMS\/Celgene, Kite, a Gilead Company, Miltenyi Biotec, Novartis, Adicet Bio, Mustang Bio, and Roche, research funding from Kite, a Gilead Company, Roche, Takeda, and Celgene and travel support from Kite, a Gilead Company, Miltenyi Biotec, Novartis, and Roche (all to institution).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}